[go: up one dir, main page]

UA99094C2 - Method for the treatment of patients with autoantibody positive disease - Google Patents

Method for the treatment of patients with autoantibody positive disease

Info

Publication number
UA99094C2
UA99094C2 UAA200806028A UAA200806028A UA99094C2 UA 99094 C2 UA99094 C2 UA 99094C2 UA A200806028 A UAA200806028 A UA A200806028A UA A200806028 A UAA200806028 A UA A200806028A UA 99094 C2 UA99094 C2 UA 99094C2
Authority
UA
Ukraine
Prior art keywords
patients
treatment
positive disease
autoantibody positive
relates
Prior art date
Application number
UAA200806028A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Марк Червир
Уилльям Фримут
Чженшао Чжун
Дениэл Оденхеймер
Мелисса Д. Перкинс
Original Assignee
Хьюман Дженом Сайенсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хьюман Дженом Сайенсиз, Инк. filed Critical Хьюман Дженом Сайенсиз, Инк.
Publication of UA99094C2 publication Critical patent/UA99094C2/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to methods and compositions for use in treatment of patients with autoantibody positive disease. In a specific embodiment, the present invention relates to a method of treating a patient that has an ANA titer of 1:80 or greater and/or greater than or equal to 30 IU/ml of anti-dsDNA antibodies in his/her blood plasma or serum comprising administering a therapeutically effective amount of an immunomodulatory agent, such as an antagonist of Neutrokine-alpha.
UAA200806028A 2005-10-13 2006-10-05 Method for the treatment of patients with autoantibody positive disease UA99094C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72562505P 2005-10-13 2005-10-13

Publications (1)

Publication Number Publication Date
UA99094C2 true UA99094C2 (en) 2012-07-25

Family

ID=41003475

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200806028A UA99094C2 (en) 2005-10-13 2006-10-05 Method for the treatment of patients with autoantibody positive disease

Country Status (3)

Country Link
CN (1) CN101512007A (en)
CR (1) CR9968A (en)
UA (1) UA99094C2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102533996B (en) * 2012-01-04 2013-06-05 南通大学附属医院 Method for determining APRIL (A Proliferation-inducing Ligand) gene promoter and transcription factor binding site and use
CN105693848A (en) * 2014-07-13 2016-06-22 马海龙 Aptamer NKXA7 specifically for Neutrokine-alpha protein and application of aptamer NKXA7
CN104177488B (en) * 2014-07-13 2016-09-14 北京博奥医学检验所有限公司 One species specificity is for the aptamer of Neutrokine-α albumen and application thereof
CN105732801A (en) * 2014-07-13 2016-07-06 马海龙 Aptamer NKXA13 specifically aiming at Neutrokine-alpha protein and application thereof
CN105732803A (en) * 2014-07-13 2016-07-06 马海龙 Aptamer NKXA6 specifically aiming at Neutrokine-alpha protein and application thereof
CN105732804A (en) * 2014-07-13 2016-07-06 马海龙 Aptamer NKXA4 specifically aiming at Neutrokine-alpha protein and application thereof
CN105732799A (en) * 2014-07-13 2016-07-06 马海龙 Aptamer NKXA18 specifically aiming at Neutrokine-alpha protein and application thereof
CN105753967A (en) * 2014-07-13 2016-07-13 马海龙 Nucleic acid aptamer NKXA14 specifically aiming at Neutrokine-alpha protein and application thereof
CN105732802A (en) * 2014-07-13 2016-07-06 马海龙 Aptamer NKXA11 specifically aiming at Neutrokine-alpha protein and application thereof
CN105693846A (en) * 2014-07-13 2016-06-22 马海龙 Aptamer NKXA10 specifically for Neutrokine-alpha protein and application of aptamer NKXA10
CN105693849A (en) * 2014-07-13 2016-06-22 马海龙 Aptamer NKXA5 specifically for Neutrokine-alpha protein and application of aptamer NKXA5
CN105732800A (en) * 2014-07-13 2016-07-06 马海龙 Aptamer NKXA15 specifically aiming at Neutrokine-alpha protein and application thereof
CN105693847A (en) * 2014-07-13 2016-06-22 马海龙 Aptamer NKXA9 specifically for Neutrokine-alpha protein and application of aptamer NKXA9
CN105713083A (en) * 2014-07-13 2016-06-29 马海龙 Specific aptamer NKXA17 for Neutrokine-alpha protein and application of specific aptamer NKXA17
CA2973423C (en) * 2015-02-09 2023-09-05 Ucb Biopharma Sprl Pharmaceutical formulation
CN113075400B (en) * 2021-03-29 2022-07-22 广州市妇女儿童医疗中心 Application of anti-double-stranded DNA antibody as a diagnostic marker for Hirschsprung's disease
CN113075410B (en) * 2021-03-29 2022-08-16 广州市妇女儿童医疗中心 Application of anti-nRNP/Sm antibody as diagnosis marker of congenital megacolon

Also Published As

Publication number Publication date
CN101512007A (en) 2009-08-19
CR9968A (en) 2008-08-18

Similar Documents

Publication Publication Date Title
UA99094C2 (en) Method for the treatment of patients with autoantibody positive disease
NZ597082A (en) Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases
LUC00011I2 (en)
UA101309C2 (en) Activin-actrii antagonists thereof and uses for increasing red blood cell levels
SG146653A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
WO2006008639A8 (en) Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
WO2007113648A3 (en) Ctla4 antibody combination therapy
IS8432A (en) Antibodies that bind to leukocyte receptor-4
RS20050344A (en) Treatment for hemorrhagic shock
EA200800397A1 (en) TIZANIDINE COMPOSITIONS AND TREATMENT METHODS USING COMPOSITIONS
WO2004103297A3 (en) Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
WO2007056301A3 (en) Antibody therapy for treatment of diseases associated with gluten intolerance
MA27699A1 (en) VACCINE AGAINST HCV
HK1121670A1 (en) Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
TW200806293A (en) Methods of treatment with CETP inhibitors
WO2006137938A3 (en) Antibody fragments for protection from pathogen infection and methods of use thereof
WO2008060535A3 (en) Use of reversine and analogs for treatment of cancer
WO2006044107A3 (en) Method of treating human preeclampsia employing resibufagenin
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
UA103907C2 (en) Normal;heading 1;heading 2;heading 3;THERAPEUTIC REGIMEN COMPRISING PEG-INTERFERON, RIBAVIRIN AND VX-950 FOR THE TREATMENT OF HEPATITIS
TW200500073A (en) Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof
WO2003032895A3 (en) Methods and pharmaceutical compositions for stimulating the immune system and/or treating cancer
UA70188C2 (en) Method for treating patients with chronic cardiac insufficiency